drug · protein
terlipressin
Marketedupdated 3mo agoby $BIVI BIOVIE INC.🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 7 investigational indications.
targets
Vasopressin V1 receptorVasopressin V2 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying terlipressin
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 14, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Apr 5, 2037method-of-use (U-3711)US 10335452
FDA exclusivities (2)
- Sep 14, 2029ODE-406Orphan Drug (7y)3.1y
- Sep 14, 2027NCENew Chemical Entity (5y)1.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 53m ago
Found something off?
comments(0)
5-min edit window · permanent after that